Eli Lilly (LLY) and Novo Nordisk (NVO) are two of the top GLP-1 makers with their revolutionary injectable treatments, with a market cap that could skyrocket in the future. But is there more to the GLP-1 story? Which competitors could come close?
Tema ETFs Founder and CEO Maurits Pot joins Market Domination to give insight into which GLP-1 makers are worthy of investor portfolios.
Pots believes that eventually, competition will catch up to Eli Lilly and Novo: “We think actually over time this is going to be a 4 to 6 horse race because right now you only have one device which is injectable going after one treatment, which is weight loss. But we’re seeing innovation in parts of the market where we’re looking at people looking at oral instead of injectable. People are looking at applications beyond weight loss.”
He continues with his picks for who can come close: “We think Amgen (AMGN) is very interesting working on a lower frequency of dosage approach. Alnylam (ALNY) is taking a more genetics approach, which again is unproven, but the early data is pretty promising. And looking at the way you could use genetics to actually treat or to address the underlying obesity issue is a is a challenge that not many people are focused on.”
For more expert insight and the latest market action, click here to watch this full episode of Market Domination.
This post was written by Nicholas Jacobino